STOCK TITAN
  1. Home
  2. Sec-filings
  3. AXSM
  4. [Form 4] Axsome Therapeutics, Inc Insider Trading Activity

Axsome Executive Nets $5M Profit in Planned Stock Sale

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Hunter R. Murdock, General Counsel of Axsome Therapeutics (AXSM), executed a series of pre-planned transactions under a 10b5-1 trading plan over three consecutive days from June 16-18, 2025.

The transactions followed a consistent pattern each day:

  • Exercised 7,500 stock options at $29.91 per share
  • Immediately sold 7,500 shares at weighted average prices between $100.26-$102.42

Total transaction summary:

  • Exercised: 22,500 options
  • Sold: 22,500 shares
  • Remaining options: 29,883
  • Net proceeds per share: approximately $70-72 (sale price minus exercise price)

These transactions were executed according to a pre-approved trading plan, which helps protect executives from insider trading allegations by establishing trade parameters in advance.

Positive

  • None.

Negative

  • None.
Insider Murdock Hunter R.
Role General Counsel
Sold 22,500 shs ($2.28M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 7,500 $0.00 --
Exercise Common Stock 7,500 $29.91 $224K
Sale Common Stock 7,500 $100.90 $757K
Exercise Stock Option (Right to Buy) 7,500 $0.00 --
Exercise Common Stock 7,500 $29.91 $224K
Sale Common Stock 7,500 $100.26 $752K
Exercise Stock Option (Right to Buy) 7,500 $0.00 --
Exercise Common Stock 7,500 $29.91 $224K
Sale Common Stock 7,500 $102.42 $768K
Holdings After Transaction: Stock Option (Right to Buy) — 29,883 shares (Direct); Common Stock — 7,500 shares (Direct)
Footnotes (1)
  1. Such transaction was pursuant to a pre-approved 10b5-1 plan. Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $101.01 and $104.09 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $100.00 and $101.53. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $100.00 and $101.96.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Murdock Hunter R.
(Last) (First) (Middle)
C/O AXSOME THERAPEUTICS, INC.
ONE WORLD TRADE CENTER, 29TH FLOOR
(Street)
NEW YORK NY 10007
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Axsome Therapeutics, Inc. [ AXSM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/16/2025 M(1) 7,500 A $29.91 7,500 D
Common Stock 06/16/2025 S(1)(2) 7,500 D $102.42(3) 0 D
Common Stock 06/17/2025 M(1) 7,500 A $29.91 7,500 D
Common Stock 06/17/2025 S(1)(2) 7,500 D $100.26(4) 0 D
Common Stock 06/18/2025 M(1) 7,500 A $29.91 7,500 D
Common Stock 06/18/2025 S(1)(2) 7,500 D $100.9(5) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $29.91 06/16/2025 M(1) 7,500 03/04/2023 03/04/2032 Common Stock 7,500 $0.00 44,883 D
Stock Option (Right to Buy) $29.91 06/17/2025 M(1) 7,500 03/04/2023 03/04/2032 Common Stock 7,500 $0.00 37,383 D
Stock Option (Right to Buy) $29.91 06/18/2025 M(1) 7,500 03/04/2023 03/04/2032 Common Stock 7,500 $0.00 29,883 D
Explanation of Responses:
1. Such transaction was pursuant to a pre-approved 10b5-1 plan.
2. Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
3. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $101.01 and $104.09
4. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $100.00 and $101.53.
5. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $100.00 and $101.96.
/s/ Hunter Murdock 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider trading activity occurred at AXSM on June 16-18, 2025?

Hunter R. Murdock, AXSM's General Counsel, executed a series of stock option exercises and sales over three days. Each day, he exercised 7,500 stock options at $29.91 per share and immediately sold the resulting shares at average prices ranging from $100.26 to $102.42.

How many AXSM stock options does Hunter Murdock have remaining after the June 2025 transactions?

After the reported transactions, Hunter Murdock retained 29,883 stock options (right to buy) with an exercise price of $29.91 and expiration date of March 4, 2032.

What was the total value of AXSM shares sold by Hunter Murdock in June 2025?

Hunter Murdock sold a total of 22,500 shares over three days at weighted average prices of $102.42, $100.26, and $100.90, generating approximate gross proceeds of $2.3 million before accounting for the option exercise costs.

Was AXSM insider Murdock's June 2025 trading planned in advance?

Yes, according to the filing footnotes, all transactions were executed pursuant to a pre-approved 10b5-1 trading plan, which is designed to comply with insider trading regulations.

What is the exercise price and expiration date of Hunter Murdock's remaining AXSM stock options?

Murdock's remaining stock options have an exercise price of $29.91 per share and expire on March 4, 2032. These options became exercisable starting March 4, 2023.